NCT02626481 2026-04-07
IFM2014-04
University Hospital, Lille
Phase 2 Completed
Clinical Trials
27 trialsNCT05099471 2025-11-28
VIWA-1
University of Ulm
Phase 2 Recruiting
NCT03367156 2025-11-12
Dexamethasone in Controlling Dyspnea in Patients With Cancer
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT03590652 2025-10-21
Daratumumab, Ixazomib, Pomalidomide, and Dexamethasone as Salvage Therapy in Relapsed/Refractory Multiple Myeloma
University of California, San Diego
Phase 2 Terminated
NCT05145400 2025-09-26
Isa-Rd for Frail and/or Much Older Patients With Newly Diagnosed Multiple Myeloma
UNC Lineberger Comprehensive Cancer Center
Phase 2 Recruiting
NCT03314181 2025-08-14
A Study of Combination Therapy With Venetoclax, Daratumumab and Dexamethasone (With and Without Bortezomib) in Participants With Relapsed or Refractory Multiple Myeloma
AbbVie
Phase 2 Active not recruiting
NCT01946477 2025-06-06
POM MM 014
Celgene
Phase 2 Completed
NCT04782687 2025-01-16
Study of Selinexor Plus DRd for Newly Diagnosed Multiple Myeloma
US Oncology Research
Phase 2 Active not recruiting
NCT04508400 2024-01-09
Fosaprepitant for the Prevention of Chemotherapy-induced Nausea and Vomiting in Pediatric Patients
Sun Yat-sen University
Phase 2 Completed
NCT05147493 2022-03-29
A Phase 2 Study of Isatuximab in Combination With Bortezomib, Cyclophosphamide and Dexamethasone Followed by Isatuximab and Lenalidomide Maintenance in Newly Diagnosed Patients With Multiple Myeloma and Severe Renal Impairment
Hellenic Society of Hematology
Phase 2 Unknown
NCT05298683 2022-03-28
A Phase 2 Study of Isatuximab in Combination With Pomalidomide and Dexamethasone in MM Patients Who Received One Prior Line of Therapy Containing Lenalidomide and a Proteasome Inhibitor
Hellenic Society of Hematology
Phase 2 Unknown
NCT03567616 2021-06-30
A Study of Venetoclax in Combination With Pomalidomide and Dexamethasone in Participants With Relapsed or Refractory Multiple Myeloma
AbbVie
Phase 2 Terminated
NCT04430361 2020-06-12
the Efficacy and Safety of 5-HT3 Receptor Antagonist, Dexamethasone or Megestrol Acetate Dispersible Tablets in the Control of Nausea and Vomiting Induced by Highly Emetogenic Chemotherapy
Henan Cancer Hospital
Phase 2 Unknown
NCT04001725 2019-11-13
OPTIMAL
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Phase 2 Unknown
NCT03785184 2019-08-28
A Study of Venetoclax Plus Lenalidomide and Dexamethasone for the Treatment of Newly Diagnosed t(11;14)-Positive Multiple Myeloma in Subjects Who Are Ineligible for High-Dose Therapy
AbbVie
Phase 2 Withdrawn
NCT02410382 2019-05-14
Dexamethasone for Treatment of Radiation-related Fatigue in Patients Receiving RT for Head-neck and Lung Cancer
University of Arizona
Phase 2 Terminated
NCT00609765 2017-03-23
Avastin, Fluorouracil, Doxorubicin and Streptozocin in Locally Advanced and Metastatic Pancreatic Endocrine Tumors
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Terminated
NCT00600353 2017-03-09
Multi-day Doses in Prevention of Nausea and Emesis
University of Kansas Medical Center
Phase 2 Completed
NCT01909856 2015-12-04
The Efficacy and Safety of Palonosetron in Preventing the Gastrointestinal Reactions Induced by 3-day Highly Emetogenic Chemotherapy
Jiangsu Simcere Pharmaceutical Co., Ltd.
Phase 2 Completed
NCT00250718 2015-08-03
Study: Treatment of Relapsed Lymphoid Malignancies With an Anti-Angiogenic Approach
New Mexico Cancer Research Alliance
Phase 2 Terminated
NCT00131261 2015-07-08
Clinical Trial of PXD101 in Patients With Advanced Multiple Myeloma
Valerio Therapeutics
Phase 2 Completed
NCT00060944 2014-09-08
A Study to Assess Treatment With 2 Different Dosing Schedules of Trabectidin Administered to Patients With Advanced Cancer
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Phase 2 Completed
NCT00441168 2014-03-21
Velcade (Bortezomib), Adriamycin Dexamethasone (PAD) or Vincristine Adriamycin Dexamethasone in Second Line Treatment of Multiple Myeloma
Janssen-Cilag International NV
Phase 2 Terminated
NCT00247416 2014-03-07
Effects of Carboplatin and Gemcitabine on Stage IIIB Pleural Effusion and Stage IV Lung Cancer
University of Kentucky
Phase 2 Completed
NCT00050414 2013-01-10
A Study of Trabectedin in Patients With Advanced Ovarian Cancer
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Phase 2 Completed
NCT00050440 2013-01-08
Phase 2 Study of ET-743 (Trabectedin) in Patients With Persistent or Recurrent Endometrial Carcinoma
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Phase 2 Completed
NCT01046461 2012-02-17
RAD
Hallym University Medical Center
Phase 2 Unknown